Cure8 research brief
This study suggests a laboratory compound (gramine) can reduce inflammation and cell death linked to ferroptosis in experimental ulcerative colitis models by interacting with COX-2. If findings translate, they could point to new therapeutic targets or adjunct approaches for protecting the intestinal barrier in IBD.
Researchers studying IBD mechanisms or new drug leads, translational scientists focused on ferroptosis or COX-2 pathways, and clinicians interested in emerging preclinical IBD research.
This PubMed abstract reports preclinical work testing gramine (GRA), an alkaloid from Arundo donax, in models of ulcerative colitis. The authors used bioinformatics, molecular docking/SPR to show GRA binds COX-2, and tested GRA alone and combined with celecoxib (CEL) in DSS-colitis mice and LPS-stimulated colonic cells.
They found GRA reduced markers of ferroptosis, improved intestinal barrier measures, and that the GRA+CEL combination appeared more effective than either treatment alone. The paper is an experimental, mechanistic study in cells and mice — not a clinical trial.
Findings come from in vitro and mouse models reported in a journal abstract. This is preclinical research and does not establish safety or effectiveness in humans. Combination effects with celecoxib were observed experimentally but require clinical testing before any treatment implications.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study reports a newly discovered class of marine-derived meroterpenoids and identifies a lead compound that reduced inflammatory markers and improved colitis in mice, which could eventually inform new drug...
The study describes a new small-molecule approach that reduced inflammation in mouse models of ulcerative colitis by targeting NF-κB transcription (p65 G-quadruplex). That suggests a potential future drug pathway...
This study suggests an existing antimalarial drug, artemisinin, may reduce inflammation and improve gut barrier function in a mouse model of ulcerative colitis by targeting CD40 — a pathway relevant to immune-driven gut...
